Aug 25 (Reuters) – U.S. drug distributor McKesson said on Tuesday it would buy clinical research and biopharma commercialization services provider Precision Medicine Group in a deal valued at about $2.25 billion.
The acquisition will expand McKeeson’s clinical research and commercialization capabilities and broaden its offerings to biopharma customers.
McKesson did not disclose an expected timeline for completing the transaction.
McKesson said Precision will become part of its Oncology & Multispecialty segment after the deal closes.
(Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru; Editing by Jonathan Ananda)
